Incyte Corporation (NASDAQ: INCY) reported a strong Q4 2025 revenue of $1.51 billion, marking a 28% increase from the previous year, despite facing a negative market reaction that saw stock prices decrease to $101.68. Surpassing Wall Street expectations, the company's results have led hedge funds to label Incyte as one of the top immunotherapy stocks to invest in, forecasting over 30% core business growth and an anticipated sales surge for Jakafi in 2026. With recent collaborations with industry giants like Novartis and Eli Lilly, Incyte is strategically positioned for continued success in oncology and autoimmunity therapies.
“Incyte Corporation (NASDAQ:INCY) · is · one of the best immunotherapy stocks to buy · according to hedge funds”
“Incyte Corporation (NASDAQ:INCY) · announced · financial results · for fiscal Q4 and the full year ended December 31, 2025”
“Incyte Corporation (NASDAQ:INCY) · reported · a total revenue · of $1.51 billion for the quarter”
“Incyte Corporation (NASDAQ:INCY) · focuses on · oncology, hematology, inflammation, and autoimmunity therapeutic areas”
“Incyte Corporation · is · one of the best NASDAQ growth stocks to buy for the next 2 years · true”
“Incyte Corporation · reported that the company’s Q4 2025 revenue climbed · 28% to $1.51 billion · true”
“Incyte Corporation · reported that full-year sales reached · $5.14 billion · true”
“Incyte Corporation · saw a year-over-year growth of its core business · 53% · true”
“Incyte Corporation · expects core business growth of over · 30% · true”
“Incyte Corporation · anticipates a sales increase for Jakafi in · 2026 · true”
“Incyte Corporation · has collaboration and license agreements with · Novartis, Lilly, and Syndax · true”
“Eli Lilly and Company and Incyte Corporation · co-developed · OLUMIANT · a small-molecule JAK inhibitor”